We assessed theuse of a dissociation We assessed the DELFIA system for use in measuring TSH in routine clinical practice.
Recently, several sensitive assays have been developed for measuring thyrotropin (thyroid-stimulating hormone, TSII) with use of monoclonal antibodies.' In most of the commerdaily available assays inimunoradiometric techniques are used (1) (2) (3) (4) (5) (6) (7) , for which assay sensitivities down to 0.08 miiimt. unitlL are claimed. However, these assays have poor precision for the lower TSH concentrations, and their maximum practical working sensitivity (i.e., CV 10%) is 0.5 mu-mt. unitfL (8), which is within the euthyroid range. Sensitivity can be improved by using a chemiluminescent (9) or a modified fluorescent label, such as the europium label used in the dissociation-enhanced lanthanide fluoroimmunoassay (DKInA) system of LKB-Wallac, P.O. Box 10,
SF-20101 Turku 10, Finland (10).
We assessed the DELFIA system for use in measuring TSH in routine clinical practice.
Materials and Methods
The DELFIA TSH assay is a two-site fluoroimmunoassay based on a direct "sandwich" technique, in which two monoclonal antibodies directed against two separate determinants on the TSH molecule are used. Europium is bound to one of these monoclonal antibodies, which, when it is placed in an enhancement solution, fluoresces strongly (10, 11). This system is said to have a sensitivity for TSH of 0.03 We measured TSH, total thyroxin (T4), free-thyroxin (FF4), and triiodothyronine (T3) in the serum of 142 patients who were being routinely assessed for thyroid function. FF4 was determined with the "Amerlex M" kit (Amersham International PLC, White Lion Road, Amersham, Bucks., England, HP7 9LL); T3 and T4 were measured with an in-house radioimniunoassay.
The patients had been evamined and designated clinically as euthyroid (94), hypothyroid (17 treated, 14 untreated), or hyperthyroid (seven treated, 12 untreated).
Results and Discussion
The DELFIA TSH assay best indicated hyperthyroidism 
FF4 and TSH
showed the same sensitivities in detecting hypothyroidism (13 of 14 clinically hypothyroid patients), while T4 and T3 showed lower sensitivities (10 of 14, and nine of 14, respectively).
FF4 was the most specific (lowest number of falsely high or low results) assay in detecting thyroid disorders, with a specificity of 93.6% as compared with 85.1% for TSH, 81.9% for T4, and 77.6% for P3. The large number of low P3 values in euthyroid patients can be attributed to the "sick euthyroid syndrome," where there is increased conversion of T4 to "reverse P3," leading to lowered P3 values but normal T4 values (12, 13). We saw here no problems associated with erroneously low values for FF4 when albumin concentrations are low as is commonly found in very ii patients.
The effect of low albumin values on results for FF4 has been shown to be quite small (19), and with the re-formulated kit (the Amerlex-M FF4 RIA kit) that we used in this study, even analbuminemic sera had only a minimal effect upon FF4 values (17, 18) .
A recent report indicating very low TSH values in very ill patients (13) was not borne out in this study.
In the treated hypothyroid group, all six patients with TSH values of <0.05 milli-int. unit/L also had increased values for FF4, suggesting overtreatment. Although five of these patients also had high T4 values, only one had increased P3 and another had a decreased P3 value. Of the seven patients who had increased TSH values only one patient showed decreased values for P3, T4, and FF4.
In three of the hyperthyroid patients undergoing treatment, values for P4, P3, and FF4 were within the normal reference interval. All the other patients had above-normal values. By contrast, only one patient had a TSH value within the normal reference interval.
We conclude that the DELFIA system is an excellent means of TSH assay: simple, precise, and readily enabling differentiation of hyperthyroid from euthyroid patients. However, we think that the assay is not yet suitable for use as a first- 
